Patents by Inventor Dal OYAMA

Dal OYAMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for oral administration
    Patent number: 10583087
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 10, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yumiko Suda, Toshiro Sakai, Ryo Kojima, Dal Oyama, Koji Nishimura, Kumi Naiki
  • Pharmaceutical composition for oral administration
    Patent number: 10548845
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 4, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yumiko Suda, Toshiro Sakai, Ryo Kojima, Dal Oyama, Koji Nishimura, Kumi Naiki
  • PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
    Publication number: 20180116965
    Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
    Type: Application
    Filed: April 27, 2016
    Publication date: May 3, 2018
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yumiko SUDA, Toshiro SAKAI, Ryo KOJIMA, Dal OYAMA, Koji NISHIMURA, Kumi NAIKI